CDK6 and acute lymphoblastic leukemia: In a recent study of De Dominici et al. investigating BCR-ABL1-positive ALL, PROTAC YX-2-107 was designed to bind CDK4/6, reducing CDK6 enzymatic activity and inducing degradation in vitro.